prod:prod_dcx-login
Xpert® Norovirus
Fast detection of Norovirus GI & GII with results available in 90 minutes
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
10 Tests
GXNOV-CE-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Collection devices
Single Use Disposable Swab (Pack of 120)
SDPS-120
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support
The Need
- Norovirus is highly contagious and is the most common cause of acute gastroenteritis worldwide1,2
- Globally, an estimated 685 million cases of norovirus are seen annually, including 200 million cases amongst children under 51,2
- Norovirus causes an estimated 200,000 deaths per year, including 50,000 child deaths1,2
- Every year, this virus is estimated to cost $60 billion worldwide due to healthcare costs and lost productivity1,2
- Norovirus outbreaks in healthcare institutions require immediate implementation of infection control measures to avoid ward closures1,2
1 Norovirus Burden and trends, CDC https://www.cdc.gov/norovirus/burden.html#worldwide. Accessed November 22, 2023
2 Norovirus introduction. WHO. https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/norovirus. Accessed November 22, 2023
2 Norovirus introduction. WHO. https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/norovirus. Accessed November 22, 2023
The Solution
- Xpert Norovirus detects genotype I (GI) and genotype II (GII), which are responsible for the majority of infections
- Xpert Norovirus provides rapid results to support timely infection control measures and outbreak response3
- On-demand identification supports outbreak management enabling fast contact tracing to manage onward transmission4
3 Cleary O, et al. Evaluation of the Xpert Norovirus assay for the rapid detection of norovirus genogroups I and II in faecal specimens within a routine laboratory setting. British Journal of Biomedical Science. 2017 Dec:74(3):144-147
4 Salmona M, et al. Laboratory-based strategy using a new marketed polymerase chain reaction assay to manage diarrheic episodes among patients from rehabilitation and long-term care facilities. Am J Infect Control. 2016 Jun 1;44(6):716-8
4 Salmona M, et al. Laboratory-based strategy using a new marketed polymerase chain reaction assay to manage diarrheic episodes among patients from rehabilitation and long-term care facilities. Am J Infect Control. 2016 Jun 1;44(6):716-8
The Impact
In published implementation studies, Xpert Norovirus PCR testing has been evaluated in routine healthcare settings to assess its potential role in supporting timely laboratory diagnosis. These studies report that fast molecular results may support infection control workflows when used as part of established institutional practices.³ ⁵ ⁶ Across reported study sites, implementation of Xpert Norovirus testing was associated with reduced laboratory turnaround times compared to prior diagnostic approaches under those specific conditions. Reported findings included:
- An 89% reduction in turnaround time (from 22 hours to 2.4 hours) within the evaluated study settings⁵
- A reported reduction in unnecessary patient isolation when molecular testing results were incorporated into local infection management decisions⁶
- Estimated operational cost impacts related to bed availability and isolation practices, as described in site‑specific economic analyses⁶
- These outcomes reflect observations from published studies conducted in defined healthcare environments and may vary based on institutional workflows, infection control policies, patient populations, and local resource availability.
3 Cleary O, et al. Evaluation of the Xpert Norovirus assay for the rapid detection of norovirus genogroups I and II in faecal specimens within a routine laboratory setting. British Journal of Biomedical Science. 2017 Dec:74(3):144-147
5 Henningsson AJ, Nilsson Bowers A, Nordgren J, Quttineh M, Matussek A, Haglund S. Rapid diagnosis of acute norovirus-associated gastroenteritis: evaluation of the Xpert Norovirus assay and its implementation as a 24/7 service in three hospitals in Jönköping County, Sweden. Eur J Clin Microbiol Infect Dis. 2017 Oct;36(10):1867-1871
6 Lyer S, et al. Comparative Evaluation 2 Commercial Norovirus Real-time PCR assays for Hospital Outbreak Management. Federation of Infection society p192 11th-14th Nov. 2013
* 57 minutes with early assay termination for positive results
#values are associated with single site implementation of Xpert Norovirus
5 Henningsson AJ, Nilsson Bowers A, Nordgren J, Quttineh M, Matussek A, Haglund S. Rapid diagnosis of acute norovirus-associated gastroenteritis: evaluation of the Xpert Norovirus assay and its implementation as a 24/7 service in three hospitals in Jönköping County, Sweden. Eur J Clin Microbiol Infect Dis. 2017 Oct;36(10):1867-1871
6 Lyer S, et al. Comparative Evaluation 2 Commercial Norovirus Real-time PCR assays for Hospital Outbreak Management. Federation of Infection society p192 11th-14th Nov. 2013
* 57 minutes with early assay termination for positive results
#values are associated with single site implementation of Xpert Norovirus
Related Products
Xpert SA Nasal Complete
Detection of S. aureus and MRSA in about 65 minutes
Xpert C. difficile BT
Detection of Clostridioides difficile infection with an independent call-out of binary toxin and differentiation of the 027 strain in around 45 minutes
Xpert vanA/vanB
Rapid VRE screening for active prevention, control, and outbreak management in around 48 minutes
Xpert MRSA/SA Blood Culture
MRSA and S. aureus detection from gram-positive blood culture samples in 62 minutes
Xpert Carba-R
Detection and differentiation of KPC, NDM, VIM, IMP-1, and OXA-48 in 50 minutes
Xpert MRSA NxG
Active MRSA Surveillance testing in around 70 minutes
Xpert MRSA/SA SSTI
Detect MRSA & SA Skin and Soft Tissue Infections in 62 minutes